# NCT05987241 (NCT05987241)

> Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05987241
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Muscle Invasive Bladder Urothelial Carcinoma; Muscle Invasive Renal Pelvis Urothelial Carcinoma; Muscle Invasive Ureter Urothelial Carcinoma; Muscle Invasive Urethral Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage IV Bladder Urothelial Carcinoma AJCC v7
- Interventions: Biospecimen Collection; cfDNA or ctDNA Measurement; Computed Tomography; Cystoscopy; Magnetic Resonance Imaging; Nivolumab; Questionnaire Administration; Relatlimab
- Enrollment: 992
- Primary outcome: Proportion of patients who are circulating tumor DNA negative (ctDNA[-]) (Cohort A Phase II)
- Primary outcome: Overall survival (OS) (Cohort A Phase III)
- Primary outcome: Disease-Free Survival (DFS) (Cohort B)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05987241